RUNX1 and acute myeloid leukemia: Herein, AML is further subclassified into: (i) AML with recurrent genetic abnormalities (including t(8;21); inv(16); PML-RARA; t(9;11); t(6;9); inv(3); t(1;22); BCR-ABL; nucleophosmin (NPM1) mutations; biallelic CEBPA mutations and AML with RUNX1 mutations as a provisional entity), (ii) AML with myelodysplasia related changes, (iii) therapy related myeloid neoplasm, (iv) AML, not otherwise specified, (v) myeloid sarcoma and (vi) myeloid proliferations related to Down Syndrome.